<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02065479</url>
  </required_header>
  <id_info>
    <org_study_id>UFJ 2014-12</org_study_id>
    <secondary_id>IRB201702750</secondary_id>
    <nct_id>NCT02065479</nct_id>
  </id_info>
  <brief_title>A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:</brief_title>
  <official_title>A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients With Coronary Artery Disease Undergoing PCI With CYP2C19 Loss-of-function Genotypes: A Feasibility Study With Point-of-care Pharmacodynamic and Genetic Testing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Numerous studies have shown that pharmacodynamics (PD) response profiles vary among&#xD;
      clopidogrel treated patients and that individuals with reduced response have an increased&#xD;
      risk of recurrent ischemic events. There are multiple factors contributing to clopidogrel&#xD;
      response variability, including genetic variations of the cytochrome P450 (CYP) 2C19 enzyme.&#xD;
      In particular, loss-of-function (LOF) alleles of the CYP2C19 enzyme reduce transformation of&#xD;
      clopidogrel pro-drug into its active metabolite. Thus, patients carrying LOF alleles have&#xD;
      lower levels of clopidogrel's active metabolite as well as diminished platelet inhibition,&#xD;
      which translates into an increased rate of adverse cardiovascular events, particularly in the&#xD;
      setting of percutaneous coronary intervention (PCI). Prasugrel and ticagrelor are novel&#xD;
      generation P2Y12 receptor inhibitors characterized by greater PD potency and reduced ischemic&#xD;
      event rates compared with clopidogrel, and are not affected by CYP2C19 LOF polymorphisms.&#xD;
      However, to date there are limited head-to-head PD comparisons between these two new P2Y12&#xD;
      receptors blockers, and there are no studies assessing on how these agents behave among&#xD;
      CYP2C19 LOF carriers. The aim of the present study is to compare the PD effects of prasugrel&#xD;
      versus ticagrelor in patients undergoing PCI with CYP2C19 LOF alleles using the novel&#xD;
      point-of-care genetic testing Spartan RX-CYP2C19 which permits accurate and rapid&#xD;
      identification of CYP2C19 genetic status.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clopidogrel is the most broadly utilized platelet P2Y12 receptor inhibitor. However, numerous&#xD;
      studies have shown that pharmacodynamics (PD) response profiles vary among clopidogrel&#xD;
      treated patients and that individuals with reduced response have an increased risk of&#xD;
      recurrent ischemic events. There are multiple factors contributing to clopidogrel response&#xD;
      variability. Among these, genetic variations of the cytochrome P450 (CYP) 2C19 enzyme, a key&#xD;
      contributor to clopidogrel metabolism, have been involved. In particular, loss-of-function&#xD;
      (LOF) alleles of the CYP2C19 enzyme reduce transformation of clopidogrel pro-drug into its&#xD;
      active metabolite. Thus, patients carrying LOF alleles have lower levels of clopidogrel's&#xD;
      active metabolite as well as diminished platelet inhibition, which translates into an&#xD;
      increased rate of adverse cardiovascular events, particularly in the setting of percutaneous&#xD;
      coronary intervention (PCI). Because of these findings, drug regulating authorities have&#xD;
      provided a boxed warning on the product label of clopidogrel on the potential for reduced&#xD;
      efficacy of clopidogrel among CYP2C19 LOF carriers and suggested considering alternative&#xD;
      antiplatelet therapies for these individuals. Prasugrel and ticagrelor are novel generation&#xD;
      P2Y12 receptor inhibitors characterized by greater PD potency and reduced ischemic event&#xD;
      rates compared with clopidogrel, and are not affected by CYP2C19 LOF polymorphisms. However,&#xD;
      to date there are limited head-to-head PD comparisons between these two new P2Y12 receptors&#xD;
      blockers, and there are no studies assessing on how these agents behave among CYP2C19 LOF&#xD;
      carriers. Tailoring antiplatelet therapy according to results of genetic testing has been&#xD;
      limited in real world clinical practice because of not having readily accessible results of&#xD;
      individual's genetic makeup. The aim of the present study is to compare the PD effects of&#xD;
      prasugrel versus ticagrelor in patients undergoing PCI with CYP2C19 LOF alleles using the&#xD;
      novel point-of-care genetic testing Spartan RX-CYP2C19 which permits accurate and rapid&#xD;
      identification of CYP2C19 genetic status.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">April 22, 2019</completion_date>
  <primary_completion_date type="Actual">April 22, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet Reactivity</measure>
    <time_frame>24 hours post loading dose</time_frame>
    <description>The primary endpoint is P2Y12 reaction unit (PRU) measured by the Verify Now P2Y12 assay 24hours/hospital discharge post randomization to prasugrel vs ticagrelor. PRU is is an arbitrary unit of measure to assess ADP-induced platelet aggregation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Comparison of platelet reactivity between prasugrel and ticagrelor</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Effient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Comparison of platelet reactivity between prasugrel and ticagrelor</description>
    <arm_group_label>Prasugrel</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion criteria:&#xD;
&#xD;
               1. Patients scheduled for left heart catheterization and undergoing PCI&#xD;
&#xD;
               2. Age 18-75 years&#xD;
&#xD;
               3. On aspirin (81mg) or aspirin (81mg) and clopidogrel (75mg/day)&#xD;
&#xD;
               4. Presence of at least one 2C19 LOF allele&#xD;
&#xD;
          -  Exclusion criteria:&#xD;
&#xD;
               1. Known allergies to aspirin, prasugrel, ticagrelor, or clopidogrel&#xD;
&#xD;
               2. Age &gt;75 years&#xD;
&#xD;
               3. Weight &lt;60kg&#xD;
&#xD;
               4. Considered at high risk for bleeding&#xD;
&#xD;
               5. History of ischemic or hemorrhagic stroke or transient ischemic attack&#xD;
&#xD;
               6. Known severe hepatic dysfunction&#xD;
&#xD;
               7. On treatment with oral anticoagulant therapy (Vitamin K antagonists, dabigatran,&#xD;
                  apixaban, rivaroxaban)&#xD;
&#xD;
               8. Use of glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban)&#xD;
&#xD;
               9. Blood dyscrasia or bleeding diathesis&#xD;
&#xD;
              10. Platelet count &lt;80x106/mL&#xD;
&#xD;
              11. Hemoglobin &lt;10 g/dL.&#xD;
&#xD;
              12. Active bleeding or hemodynamic instability&#xD;
&#xD;
              13. Creatinine Clearance &lt;30 mL/minute&#xD;
&#xD;
              14. Patients with sick sinus syndrome (SSS) or high degree AV block without pacemaker&#xD;
                  protection.&#xD;
&#xD;
              15. Current treatment with drugs interfering with CYP3A4 metabolism (to avoid&#xD;
                  interaction with Ticagrelor): Ketoconazole, itraconazole, voriconazole,&#xD;
                  clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir,&#xD;
                  atazanavir, and telithromizycin.&#xD;
&#xD;
              16. Pregnant females* *Women of childbearing age must use reliable birth control&#xD;
                  (i.e. oral contraceptives) while participating in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominick J Angiolillo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 12, 2014</study_first_submitted>
  <study_first_submitted_qc>February 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2014</study_first_posted>
  <results_first_submitted>August 7, 2020</results_first_submitted>
  <results_first_submitted_qc>August 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2020</results_first_posted>
  <last_update_submitted>August 27, 2020</last_update_submitted>
  <last_update_submitted_qc>August 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Genetic Polymorphism</keyword>
  <keyword>Pharmacodynamic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT02065479/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ticagrelor</title>
          <description>The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.&#xD;
Prasugrel: Comparison of platelet reactivity between prasugrel and ticagrelor</description>
        </group>
        <group group_id="P2">
          <title>Prasugrel</title>
          <description>The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.&#xD;
Ticagrelor: Comparison of platelet reactivity between prasugrel and ticagrelor</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ticagrelor</title>
          <description>The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.&#xD;
Prasugrel: Comparison of platelet reactivity between prasugrel and ticagrelor</description>
        </group>
        <group group_id="B2">
          <title>Prasugrel</title>
          <description>The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.&#xD;
Ticagrelor: Comparison of platelet reactivity between prasugrel and ticagrelor</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="8"/>
                    <measurement group_id="B2" value="60" spread="9"/>
                    <measurement group_id="B3" value="59" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes Mellitus</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Platelet Reactivity</title>
        <description>The primary endpoint is P2Y12 reaction unit (PRU) measured by the Verify Now P2Y12 assay 24hours/hospital discharge post randomization to prasugrel vs ticagrelor. PRU is is an arbitrary unit of measure to assess ADP-induced platelet aggregation.</description>
        <time_frame>24 hours post loading dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.&#xD;
Prasugrel: Comparison of platelet reactivity between prasugrel and ticagrelor</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel</title>
            <description>The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.&#xD;
Ticagrelor: Comparison of platelet reactivity between prasugrel and ticagrelor</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Reactivity</title>
          <description>The primary endpoint is P2Y12 reaction unit (PRU) measured by the Verify Now P2Y12 assay 24hours/hospital discharge post randomization to prasugrel vs ticagrelor. PRU is is an arbitrary unit of measure to assess ADP-induced platelet aggregation.</description>
          <units>PRU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" spread="41"/>
                    <measurement group_id="O2" value="33" spread="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ticagrelor</title>
          <description>The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.&#xD;
Prasugrel: Comparison of platelet reactivity between prasugrel and ticagrelor</description>
        </group>
        <group group_id="E2">
          <title>Prasugrel</title>
          <description>The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.&#xD;
Ticagrelor: Comparison of platelet reactivity between prasugrel and ticagrelor</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dypnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Dominick Angiolillo</name_or_title>
      <organization>University of Florida</organization>
      <phone>904-244-3378</phone>
      <email>dominic.angiolillo@jax.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

